Rybicki Benjamin A, Nock Nora L, Savera Adnan T, Tang Deliang, Rundle Andrew
Department of Biostatistics and Research Epidemiology, Henry Ford Health System, 1 Ford Place 3E, Detroit, MI 48202, USA.
Cancer Lett. 2006 Aug 8;239(2):157-67. doi: 10.1016/j.canlet.2005.07.029. Epub 2005 Sep 9.
The evidence for polycyclic aromatic hydrocarbons (PAH) playing a role in prostate carcinogenesis comes mainly from associations between reported PAH exposures and prostate cancer in epidemiologic studies. Associations between prostate cancer and DNA repair genotypes and phenotypes have also been reported, lending further credence to a PAH-induced carcinogenesis pathway in prostate cancer. Recent work that demonstrates the human prostate has metabolic enzyme activity necessary for PAH activation and will form DNA adducts upon exposure to PAH further supports PAH carcinogenesis. We have demonstrated the presence of PAH-DNA adducts in prostate cancer cases, but further validation of this biomarker as a carcinogenic agent in human prostate is needed.
多环芳烃(PAH)在前列腺癌发生过程中发挥作用的证据主要来自于流行病学研究中报告的PAH暴露与前列腺癌之间的关联。前列腺癌与DNA修复基因型和表型之间的关联也有报道,这进一步支持了PAH诱导前列腺癌的致癌途径。最近的研究表明,人类前列腺具有激活PAH所需的代谢酶活性,并且在接触PAH后会形成DNA加合物,这进一步支持了PAH致癌作用。我们已经在前列腺癌病例中证实了PAH-DNA加合物的存在,但需要进一步验证这种生物标志物作为人类前列腺致癌物的作用。